Neutralizing antibody responses and cellular responses against severe acute respiratory syndrome coronavirus 2 omicron subvariant BA.5 after an mRNA severe acute respiratory syndrome coronavirus 2 vaccine dose in kidney transplant recipients DOI Open Access

Keita Kawashiro,

Rigel Suzuki, Takuto Nogimori

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: Aug. 3, 2023

Abstract We examined the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein IgG antibody and neutralizing titers cellular immunity in 73 uninfected recipients 17 healthy controls who received three doses of a 2019 mRNA vaccine. Neutralizing were evaluated using GFP-carrying recombinant SARS-CoV-2 with B.1.1, omicron BA.1, or BA.5. For immunity, peripheral blood mononuclear cells stimulated peptides corresponding to antigens BA.5; spike-specific CD4/CD8 memory T intracellular cytokine staining. The median 7.8 AU/mL 143.0 (p < 0.0001). against all viral variants significantly lower number CD8 + decreased Twenty seven additionally bivalent omicron-containing booster vaccine, increased both groups; however, increase was recipients. Recipients did not gain sufficient third dose suggesting need explore methods other than vaccines.

Language: Английский

Five doses of the mRNA vaccination potentially suppress ancestral-strain stimulated SARS-CoV2-specific cellular immunity: a cohort study from the Fukushima vaccination community survey, Japan DOI Creative Commons
Yuta Tani, Morihito Takita, Masatoshi Wakui

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Aug. 16, 2023

The bivalent mRNA vaccine is recommended to address coronavirus disease variants, with additional doses suggested for high-risk groups. However, the effectiveness, optimal frequency, and number of remain uncertain. In this study, we examined long-term cellular humoral immune responses following fifth administration severe acute respiratory syndrome 2 (SARS-CoV-2) in patients undergoing hemodialysis. To our knowledge, first study monitor data on immunity dynamics populations after five vaccination, including vaccine. Whereas most maintained throughout observation period, observed reduced reactivity as measured by ancestral-strain-stimulated ELISpot assay a subset patients. Half individuals (50%; 14/28) three months dose, despite acquiring immunity. absence relationship between positive controls T-Spot suggests that these alterations were specific SARS-CoV-2. multivariable analysis, participants aged ≥70 years showed marginally significant lower likelihood having reactive results. Notably, among 14 who received heterologous vaccines, 13 successfully acquired immunity, supporting effectiveness strategy. These findings provide valuable insights future vaccination strategies vulnerable populations. further research needed evaluate involvement tolerance exhaustion through repeated optimize immunization strategies.

Language: Английский

Citations

9
Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariant BA.5 after mRNA SARS-CoV-2 vaccination in kidney transplant recipients DOI Creative Commons

Keita Kawashiro,

Rigel Suzuki, Takuto Nogimori

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 19, 2024

Abstract Although the mRNA SARS-CoV-2 vaccine has improved mortality rate in general population, its efficacy against rapidly mutating virus strains, especially kidney transplant recipients, remains unclear. We examined anti-SARS-CoV-2 spike protein IgG antibody and neutralizing titers cellular immunity B.1.1, BA.1, BA.5 antigens 73 uninfected recipients 17 healthy controls who received three doses of an vaccine. The were significantly lower than controls. Similarly, viral variants recipients. When was mutated, decreased both groups. In analysis, number spike-specific CD8 + non-naïve T cells Conversely, frequency Th2 CD4 T-cells higher that Twenty seven also a bivalent omicron-containing booster vaccine, leading to increased However, increase Recipients did not gain sufficient with third dose indicating need explore methods other vaccines.

Language: Английский

Citations

1
The Long-Term Immunogenicity of mRNABNT162b Third Vaccine Dose in Solid Organ Transplant Recipients DOI Creative Commons
Maria Antonella Zingaropoli, Mariasilvia Guardiani, Federica Dominelli

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(3), P. 224 - 224

Published: Feb. 22, 2024

We investigated humoral and T-cell response to a SARS-CoV-2 mRNA vaccine in solid organ transplant recipients (SOT-Rs) healthy donors (HDs) before (T0) after two (T1) twelve months (T2) since the third dose administration. SOT-Rs were stratified according transplanted time elapsed transplant. In SOT-Rs, detectable levels of anti-S antibodies observed 44%, 81% 88% at T0, T1 T2, respectively. Conversely, antibody detected 100% HD all points. Lower titers compared HDs, even stratifying by organs percentages responding polyfunctional T-cells as well each subgroup HDs. At both T0 T1, predominance one cytokine production shortly was observed. dynamic change subset distribution observed, similar what increased rate seroconversion, although remained lower qualitatively inferior vaccination Vaccine effectiveness is still suboptimal might be improved booster doses prophylactic strategies.

Language: Английский

Citations

1
Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients DOI Creative Commons

Keita Kawashiro,

Rigel Suzuki,

Takuto Nogimori

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: May 28, 2024

Abstract Although the mRNA SARS-CoV-2 vaccine has improved mortality rate in general population, its efficacy against rapidly mutating virus strains, especially kidney transplant recipients, remains unclear. We examined anti-SARS-CoV-2 spike protein IgG antibody and neutralizing titers cellular immunity B.1.1, BA.1, BA.5 antigens 73 uninfected recipients 16 healthy controls who received three doses of an vaccine. The were significantly lower than controls. Similarly, viral variants recipients. When was mutated, decreased both groups. In analysis, number spike-specific CD8 + non-naïve T cells Conversely, frequency Th2 CD4 T-cells higher that Nineteen six also a bivalent omicron-containing booster vaccine, leading to increase After that, eleven five XBB.1.5 monovalent vaccines, increasing not only XBB.1.5, but EG.5.1 BA.2.86 did gain sufficient Omicron with third dose humoral response mutant lineages increased after Omicron-containing Therefore, it is important for continue administer updated vaccines.

Language: Английский

Citations

0
Neutralizing antibody responses and cellular responses against severe acute respiratory syndrome coronavirus 2 omicron subvariant BA.5 after an mRNA severe acute respiratory syndrome coronavirus 2 vaccine dose in kidney transplant recipients DOI Open Access

Keita Kawashiro,

Rigel Suzuki, Takuto Nogimori

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: Aug. 3, 2023

Abstract We examined the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein IgG antibody and neutralizing titers cellular immunity in 73 uninfected recipients 17 healthy controls who received three doses of a 2019 mRNA vaccine. Neutralizing were evaluated using GFP-carrying recombinant SARS-CoV-2 with B.1.1, omicron BA.1, or BA.5. For immunity, peripheral blood mononuclear cells stimulated peptides corresponding to antigens BA.5; spike-specific CD4/CD8 memory T intracellular cytokine staining. The median 7.8 AU/mL 143.0 (p < 0.0001). against all viral variants significantly lower number CD8 + decreased Twenty seven additionally bivalent omicron-containing booster vaccine, increased both groups; however, increase was recipients. Recipients did not gain sufficient third dose suggesting need explore methods other than vaccines.

Language: Английский

Citations

0